These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens. Wilson SE; Habeshaw JA; Addawe MA; Hounsell EF; Oxford JS AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1313-24. PubMed ID: 9339848 [TBL] [Abstract][Full Text] [Related]
43. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696 [TBL] [Abstract][Full Text] [Related]
44. Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS. Ahlers JD; Belyakov IM Trends Immunol; 2010 Mar; 31(3):120-30. PubMed ID: 20089450 [TBL] [Abstract][Full Text] [Related]
45. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review. Becker Y Virus Genes; 1994 Jul; 8(3):249-70. PubMed ID: 7975271 [TBL] [Abstract][Full Text] [Related]
46. Use of helper T cell-inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of long-lasting systemic CTL response. Nehete PN; Arlinghaus RB; Sastry KJ Viral Immunol; 1994; 7(4):189-97. PubMed ID: 7576033 [TBL] [Abstract][Full Text] [Related]
47. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. Buonaguro L; Racioppi L; Tornesello ML; Arra C; Visciano ML; Biryahwaho B; Sempala SD; Giraldo G; Buonaguro FM Antiviral Res; 2002 Jun; 54(3):189-201. PubMed ID: 12062391 [TBL] [Abstract][Full Text] [Related]
48. Innate gamma/delta T-cells during HIV infection: Terra relatively Incognita in novel vaccination strategies? Agrati C; D'Offizi G; Gougeon ML; Malkovsky M; Sacchi A; Casetti R; Bordoni V; Cimini E; Martini F AIDS Rev; 2011; 13(1):3-12. PubMed ID: 21412385 [TBL] [Abstract][Full Text] [Related]
49. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. Paliard X; Liu Y; Wagner R; Wolf H; Baenziger J; Walker CM AIDS Res Hum Retroviruses; 2000 Feb; 16(3):273-82. PubMed ID: 10710215 [TBL] [Abstract][Full Text] [Related]
50. Major histocompatibility gene products and human immunodeficiency virus infection. Puppo F; Ruzzenenti R; Brenci S; Lanza L; Scudeletti M; Indiveri F J Lab Clin Med; 1991 Feb; 117(2):91-100. PubMed ID: 1993862 [TBL] [Abstract][Full Text] [Related]
51. AIDS and immune dysfunction. Alternative etiologic mechanisms. del Guercio P Contrib Microbiol Immunol; 1989; 11():289-304. PubMed ID: 2573482 [No Abstract] [Full Text] [Related]
52. Multispecific and heterogeneous recognition of the gag protein by cytotoxic T lymphocytes (CTL) from HIV-infected patients: factors other than the MHC control the epitopic specificities. Buseyne F; Janvier G; Fleury B; Schmidt D; Rivière Y Clin Exp Immunol; 1994 Sep; 97(3):353-60. PubMed ID: 7521806 [TBL] [Abstract][Full Text] [Related]
53. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies. Gorse GJ; Patel GB; Mandava MD; Belshe RB Vaccine; 1999 Dec; 18(9-10):835-49. PubMed ID: 10580197 [TBL] [Abstract][Full Text] [Related]
54. Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Kameoka M; Nishino Y; Matsuo K; Ohara N; Kimura T; Yamazaki A; Yamada T; Ikuta K Vaccine; 1994 Feb; 12(2):153-8. PubMed ID: 8147098 [TBL] [Abstract][Full Text] [Related]
55. HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides and antigens to Langerhans cells for induction of cytolytic T cells by HLA class I and CD1 molecules for long term protection. Becker Y Adv Exp Med Biol; 1996; 397():97-104. PubMed ID: 8718588 [No Abstract] [Full Text] [Related]
56. Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. Klein MR; Veenstra J; Holwerda AM; Roos MT; Gow I; Patou G; Coutinho RA; De Wolf F; Miedema F AIDS Res Hum Retroviruses; 1997 Mar; 13(5):393-9. PubMed ID: 9075480 [TBL] [Abstract][Full Text] [Related]
57. Virus-specific cytotoxic T-lymphocyte activity elicited by coimmunization with human immunodeficiency virus type 1 genes regulated by the bacteriophage T7 promoter and T7 RNA polymerase protein. Selby MJ; Doe B; Walker CM J Virol; 1997 Oct; 71(10):7827-31. PubMed ID: 9311870 [TBL] [Abstract][Full Text] [Related]
58. [Development of HIV vaccines]. Shibata R Nihon Rinsho; 2002 Apr; 60(4):790-7. PubMed ID: 11968790 [TBL] [Abstract][Full Text] [Related]
59. Proliferative T-cell response to HIV envelope glycoprotein in immunized and infected primates and human beings. Krohn K; Ranki A; Lusso P; Moss B; Ashorn P; Arthur LO; Putney SD; Gallo RC J Med Primatol; 1989; 18(3-4):363-9. PubMed ID: 2547967 [TBL] [Abstract][Full Text] [Related]
60. Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Layton GT; Harris SJ; Myhan J; West D; Gotch F; Hill-Perkins M; Cole JS; Meyers N; Woodrow S; French TJ; Adams SE; Kingsman AJ Immunology; 1996 Feb; 87(2):171-8. PubMed ID: 8698376 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]